[Biosimilars - Potential, risks and open questions].
出版信息
Dtsch Med Wochenschr. 2014 Jan;139(1-2):12-3.
PMID:24551883
Abstract
摘要
相似文献
1
[Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr. 2014 Jan;139(1-2):12-3.
2
[Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Dtsch Med Wochenschr. 2014 Nov;139(47):2399-404. doi: 10.1055/s-0034-1387371. Epub 2014 Nov 12.
3
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Health Aff (Millwood). 2014 Jun;33(6):1048-57. doi: 10.1377/hlthaff.2013.0862.
4
[The new drug cost saving package. Sensible measures or risk for patients?].
Krankenpfl J. 2002;40(5-6):159.
5
Biosimilars in Dermatology: Current Situation (Part II).
Actas Dermosifiliogr. 2015 Sep;106(7):550-4. doi: 10.1016/j.ad.2015.04.008. Epub 2015 Jun 3.
6
[The importance of biosimilars medicines for private and statutory health insurance].
Versicherungsmedizin. 2016 Dec 15;68(4):173-5.
7
Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Clin Exp Rheumatol. 2016 Jul-Aug;34(4):698-705. Epub 2016 Jul 4.
8
[Limited prescribing freedom by federal cost regulation?].
Z Arztl Fortbild Qualitatssich. 1997 Nov;91(7):633-5.
9
Demystifying biosimilars: development, regulation and clinical use.
Future Oncol. 2019 Mar;15(7):777-790. doi: 10.2217/fon-2018-0680. Epub 2018 Nov 30.
10
[Biosimilars: assessment of efficacy, safety and cost].
Farm Hosp. 2010 Mar;34 Suppl 1:25-8. doi: 10.1016/S1130-6343(10)70006-4.
Zotero 插件